{"symbol":"SYK","fiscalQuarter":"Q2-2026","reportDate":"2026-07-30","reportTime":"AMC","status":"upcoming","company":{"name":"Stryker Corporation","sector":"Health Care","industry":"Health Care Equipment"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/SYK/earnings/Q2-2026","estimates":{"consensusEps":3.6791,"consensusRevenue":6719.22,"epsLow":3,"epsHigh":3.81,"whisperEps":null,"numAnalysts":null},"preBrief":{"companySnapshot":"Stryker Corporation (SYK) is a leading medical technology company that develops and manufactures innovative healthcare equipment and devices. Operating in the health care sector, Stryker plays a crucial role in improving patient outcomes through its advanced surgical instruments, orthopedic implants, and neurotechnology solutions.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.","consensus":"$3.68"},{"name":"Revenue","why":"Revenue growth reflects the company's ability to sell its products and expand its market share.","consensus":"$6.7B"}],"lastQuarterRecap":{"summary":"In Q1 2026, Stryker reported an EPS of $2.60, which was below analysts' expectations by 12.63%. The stock did not move significantly the following day.","promises":["Focus on expanding product lines in orthopedics and neurotechnology.","Commitment to improving operational efficiency and cost management.","Plans to invest in research and development for innovative medical solutions."]},"wallStreetExpectations":{"summary":"Analysts expect Stryker to report a rebound in earnings this quarter, with a consensus EPS of $3.68. However, there is caution due to the recent earnings miss.","bullCase":"If Stryker can exceed EPS expectations and show strong revenue growth, it could signal a recovery in demand for its products, boosting investor confidence.","bearCase":"Conversely, if the company fails to meet expectations again, it may raise concerns about its market position and growth prospects, leading to a negative reaction."},"optionsSignal":{"impliedMove":"1.09%","context":"The options market is pricing in a modest move around the earnings report, suggesting uncertainty but not extreme volatility."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"-12.63%","reaction":"+0.00%"},{"quarter":"Q4-2025","epsSurprise":"+1.71%","reaction":"-0.99%"},{"quarter":"Q3-2025","epsSurprise":"+1.66%","reaction":"-0.17%"},{"quarter":"Q2-2025","epsSurprise":"+2.05%","reaction":"-1.92%"},{"quarter":"Q1-2025","epsSurprise":"+4.18%","reaction":"+0.02%"}],"pivotalQuestions":[{"question":"Will Stryker achieve an EPS of $3.68 or higher this quarter?","whyItMatters":"Meeting or exceeding this EPS target is crucial for restoring investor confidence after the previous earnings miss."},{"question":"What are the revenue figures for Stryker's orthopedic and neurotechnology segments?","whyItMatters":"These segments are vital for growth, and strong performance here could indicate a positive trend for the company."}],"thesisBreakLevels":{"bullTrigger":"Achieving an EPS of $3.68 or better with revenue exceeding $6.7B would confirm the bull case.","bearTrigger":"If EPS falls below $3.00, it would signal significant challenges for the company.","context":"This quarter's performance is critical as Stryker seeks to recover from a disappointing prior quarter and demonstrate growth potential."},"scenarioPlaybook":{"beatAndRaise":"If Stryker beats expectations, history suggests the stock could see a modest increase, confirming a recovery narrative.","inLineCautious":"An in-line report may lead to a muted response, as investors await further clarity on future growth prospects.","miss":"A miss could lead to a negative reaction, with historical data suggesting a potential decline in stock value."},"whatTheStreetIsMissing":{"thesis":"The consensus may underestimate the potential for Stryker's recovery in the orthopedic market, which has shown signs of improvement.","supportingPoints":["The company has a strong track record of innovation that could drive sales growth.","Recent trends in elective surgeries may indicate a rebound in demand for Stryker's products.","Options pricing suggests a lower expected move, indicating that the market may not fully account for potential upside."],"riskToConsensus":"If orthopedic revenue shows unexpected strength, it could challenge the current bearish sentiment."},"whatToListenFor":["Updates on sales growth in the orthopedic segment.","Any changes in guidance for the upcoming quarters.","Details on new product launches and their expected impact on revenue.","Management's perspective on market trends and competitive landscape.","Insights into cost management strategies and operational efficiencies."],"metaDescription":"Stryker Corporation (SYK) reports Q2 2026 earnings July 30. Analysts expect $3.68 EPS on $6.7B revenue. Here's what to watch."}}